Myosin light chain 1 is a novel intracellular substrate for MMP-2, and its degradation may contribute to contractile dysfunction following ischemia-reperfusion injury.
No takes yet. Share an insight, caveat, or question.
MMP-2 inhibition may preserve post-ischemic contractility via myosin light chain 1; hypothesis-generating for clinical translation.
Sawicki et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: